161 results
Page 4 of 9
8-K
EX-99.1
y5nwvozfwj khsj1gv
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
EX-99.1
10su5qkrpmts8k
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
8-K
EX-99.1
4dnhdceqe1f
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
tep5n0 7g
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
EX-99.1
08qr11qb 0r
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
EX-99.1
cywwco xj
2 Mar 20
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2019 Financial Results and Provides Corporate Update
7:43am
8-K
EX-1.1
mp5ai1
8 Jan 20
Entry into a Material Definitive Agreement
5:12pm
424B5
5dnczg6inon6ao80m0i
8 Jan 20
Prospectus supplement for primary offering
5:06pm
8-K
EX-99.2
olxuej lgf4ux
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
8-K
EX-99.3
t80m8xf8o 81wq
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
424B5
k4q5y5khoej lgz3cg
6 Jan 20
Prospectus supplement for primary offering
4:42pm
S-3ASR
pym0xcte
6 Jan 20
Automatic shelf registration
4:02pm
8-K
EX-99.1
t71b8hz0w
23 Dec 19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
8:15am
8-K
EX-99.1
7fr sq6crcfcm
5 Nov 19
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
7:40am
8-K
EX-99.1
g97u9i ta5wgaa4po7h8
10 Sep 19
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
7:39am